I agree that this is a major problem that is prevalent within the medical device industry. I had similarly posted in this forum (see “Clinical Trials” post) about how patients and engineers are effected because of the time/cost of the class 2 or class 3 process as well. I hope there will be a decrease in cost but that is a large issue within the whole medical field, and I don’t see it getting addressed any time in the near future.

I also do agree that stocks in the medical device industry are risky, but it is still heavily invested into. Large companies especially have been slowly and steadily increasing their net worth, which maintains the trust of all of the investors.